Supplementary Tables & Figures from MEK1/2 Inhibition Decreases Lactate in BRAF-Driven Human Cancer Cells

Supplementary Tables & Figures - PDF file 354K, Table S1: The amount of glucose left in the media relative to controls following 24h treatment with CI-1040 as measured by 1H MRS. Fig.S1: The effect of 0-2% DMSO treatment for 24h on cell cycle, MEK1/2 signaling and lactateE in BRAFV600D WM266.4 cells. Fig.S2: The effect of 24h treatment with carboplatin on cell cycle profiles (A), cell counts and lactateE levels (B) in BRAFV600D WM266.4 human melanoma cells.*p<0.05, n=4. Fig.S3: The effect of 24h CI-1040 and PD325901 treatment on MEK1/2 signaling, cell proliferation and cell cycle distributions in human cancer cells with varying BRAF mutation status. Fig.S4: MEK1/2 inhibition with CI-1040 (1�M, 24h) reduces hexokinase-II expression in BRAFV600E HT29 human colon cancer cells. *p=0.02, n=3. Fig.S5: Western blots showing no effect on P-AKT levels in BRAFV600D WM266.4 melanoma cells following treatment with CI-1040 (1�M). N=3